about
Immunological Evasion in GlioblastomaImmunotherapy for cancer in the central nervous system: Current and future directionsImmune Evasion Strategies of GlioblastomaEphs and Ephrins in malignant gliomasImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupNitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in GliomasImpact of temozolomide on immune response during malignant glioma chemotherapyIDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survivalLoss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma.Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cellsSignificance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.Glioblastoma multiforme: State of the art and future therapeutics.Current Studies of Immunotherapy on GlioblastomaMedulloblastoma development: tumor biology informs treatment decisionsAdvanced age negatively impacts survival in an experimental brain tumor model.Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.Improving vaccine efficacy against malignant gliomaCirculating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.The Process and Regulatory Components of Inflammation in Brain Oncogenesis.Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.Profile of patients with brain tumors and the role of nursing care.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.Modeling cancer-immune responses to therapy.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
P2860
Q26746612-66CD657D-70FA-4FF8-86FB-A5E36CAFA72AQ26750765-80FF150B-301F-4598-9B73-994DBF6EA3DCQ26765855-9010DBFF-DC87-413F-AA5C-3E4625B72E63Q27015780-B9B7F193-D21F-487B-BF96-D5119AECA8A3Q28083009-88377A0B-C986-403E-A2B2-6394C1303228Q30431810-2D1BF172-A363-41AB-ABDF-7A18D1E00D01Q33670136-2F0258BC-4014-45BC-9C5B-7ED77973ADD0Q34177641-008C0DEB-C51D-4CC8-965A-762FC3466FD5Q34276759-9A19193E-4ABE-41E1-9275-A893B37FD8D9Q35416653-47791E28-74E8-4993-9AC0-F0F1F1B0558DQ36009621-721FA908-41DA-464C-A635-5B2070DCDF6BQ36362798-6CBC4BB5-68AD-4629-82FF-171C296EA568Q36405905-1F0AFCEA-DC96-46FA-92B8-8B2CA56EF99CQ37190394-75A22661-22E1-4E8B-99A3-74B4205646DFQ37687763-6FA11AD5-D339-4735-AA63-6F55E086E631Q38203856-CAFA4465-45B1-40CB-9C71-562C4F7BD6B7Q38225874-8F69BD7F-6EA8-47D9-87CD-DC60A464208DQ38262914-E576BAD7-70DB-4AB1-A9CD-52A3A2C82E11Q38376606-AA1458B8-BC70-4931-938A-1A6A120385CFQ38753736-1F48CCA9-82B4-4D6D-BF3B-C081900C540FQ38920881-7F8B0E00-1909-4682-BA1B-0421D4DC6C93Q38953024-F51F069F-A09A-4730-B304-2B55CB19FCD6Q39100186-0C9B9A21-96AD-4241-9834-43CF4D343ED7Q39202332-BA013DFF-D739-472A-B6E5-D699ED829CEDQ45854947-A4BFD22C-A9EE-48CF-B27A-C5DB971A44A1Q47827107-0DC61450-F2DB-4434-92AD-39B4109C8C35Q50128059-8A971B5D-F8B5-4028-A88F-C20AD8CA14A8Q51029245-0A190CE6-2996-40B9-9F4E-B7B99CB65F96Q52683991-52E0559A-D87A-4FBA-9534-912323EFBCDA
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Recent developments on immunotherapy for brain cancer.
@ast
Recent developments on immunotherapy for brain cancer.
@en
type
label
Recent developments on immunotherapy for brain cancer.
@ast
Recent developments on immunotherapy for brain cancer.
@en
prefLabel
Recent developments on immunotherapy for brain cancer.
@ast
Recent developments on immunotherapy for brain cancer.
@en
P2093
P2860
P1476
Recent developments on immunotherapy for brain cancer.
@en
P2093
Maciej S Lesniak
Pragati Nigam
P2860
P304
P356
10.1517/14728214.2012.679929
P407
P577
2012-04-25T00:00:00Z